A solid pharmaceutical formulation comprising a mixture of (1) lyophilized granules comprising sildenafil or a pharmaceutically acceptable salt thereof as active ingredient and (2) a non-lyophilized composition, wherein the formulation comprises 35% to 50% by weight of the lyophilized granules (1) and dissolves in the oral cavity and the non-lyophilized composition (2) is a solid blend composition comprising flow enhancing agents, a package containing the formulation, and a process for the manufacture of the formulation.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61J 3/02 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/19 - Particulate form, e.g. powders lyophilised
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and preparations for treating blood disorders and conditions; pharmaceutical products and preparations for treating hormonal disorders and conditions; pharmaceutical products and preparations for treating urological disorders and conditions; pharmaceutical products and preparations for treating diabetes insipidus
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biological preparations for use in the pharmaceutical industry; biological preparations for scientific and research use; biological cell preparations for use in the pharmaceutical industry and for laboratory and scientific use; T-cells and gamma delta T-cells for use in the pharmaceutical industry and for laboratory and scientific use; cell cultures for use in the pharmaceutical industry and for laboratory and scientific use; biological materials for use in cellular engineering; biological materials for use in immunology research; cellular starting materials for use in the pharmaceutical industry and for laboratory and scientific use; biological preparations for use in the development of cellular therapies; biological materials for use in pharmaceutical and biomedical research Pharmaceutical and biological preparations for medical and therapeutic use; cellular preparations for medical and therapeutic use; T-cells and gamma delta T-cells for medical and therapeutic use; genetically engineered cellular preparations for medical and therapeutic use; engineered immune cell preparations for medical and therapeutic purposes; biological preparations for use in cellular therapy; cell-based therapeutic preparations; cellular therapeutic preparations for the treatment of cancer, infectious diseases and immune-related disorders Pharmaceutical and biomedical research and development services; scientific research and development in the field of biotechnology, immunology, cell therapy, immunotherapy and regenerative medicine; scientific research relating to immune cells, T-cells, gamma delta T-cells, adoptive cell therapies and cancer therapies; laboratory research relating to cellular and genetic engineering; development of engineered immune cells and cellular therapeutic products for therapeutic applications; laboratory services relating to biotechnology and cellular manipulation; clinical research services; scientific consultancy relating to biotechnology, immunotherapy and pharmaceutical development; providing scientific information relating to cellular therapies and immunotherapeutics
6.
MIXED VASOPRESSIN RECEPTOR AGONIST-ANTAGONIST FOR MODULATING MEAN ARTERIAL PRESSURE
Provided herein are compositions, such as suitable for subcutaneous administration, and methods for modulating mean arterial pressure (MAP) in an individual using a mixed V1A receptor agonist-antagonist.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
7.
METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of orthopaedic diseases and conditions; Biopharmaceutical preparations for the treatment of orthopaedic diseases and conditions
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of orthopaedic diseases and conditions; Biopharmaceutical preparations for the treatment of orthopaedic diseases and conditions
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of health issues and healthcare and dissemination of information promoting public awareness of health issues and healthcare through social awareness campaigns Educational services, namely, organizing and conducting seminars, conferences, congresses, workshops, non-downloadable webinars, in-person educational forums, and online tutorials and training in the field of healthcare; production of films and audio recordings that feature information in the field of healthcare; providing online non-downloadable audio recordings and films via video on-demand transmission services, all the foregoing featuring information in the field of healthcare; publication of magazines, books, guides, digital, and electronic media in the nature of electronic books and magazines containing information in the field of health care Providing information in the field of healthcare
Described are injectable peptide phospholipid-based phase separation gel (PPSG) pharmaceutical compositions, methods for preparing them, and therapeutic methods using them.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of health issues and healthcare and dissemination of information promoting public awareness of health issues and healthcare through social awareness campaigns Educational services, namely, organizing and conducting seminars, conferences, congresses, workshops, non-downloadable webinars, in-person educational forums, and online tutorials and training in the field of healthcare; production of films and audio recordings that feature information in the field of healthcare; providing online non-downloadable audio recordings and films via video on-demand transmission services, all the foregoing featuring information in the field of healthcare; publication of magazines, books, guides, digital, and electronic media in the nature of electronic books and magazines containing information in the field of health care Providing information in the field of healthcare
Described are lipidated GnRH analogues, wherein the GnRH analogues are lipidated at one or more of amino acid positions, such as amino acid position 1, 5, 6 and/or 8 of a GnRH analogue peptide backbone. Also described are methods of making the lipidated compounds, pharmaceutical compositions comprising the lipidated compounds, and their use in methods of treatment.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Stable liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.
Described herein are aqueous pharmaceutical compositions comprising lidocaine, hyaluronic acid, and chondroitin sulphate (or a pharmaceutically acceptable salts of any thereof) and water, as well as methods of making such aqueous pharmaceutical compositions, and therapeutic methods using them.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61B 17/43 - Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for artificial insemination
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
The present invention provides a pharmaceutical composition for intravesical administration, in particular for use in the treatment of urinary bladder disorders.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical products, preparations and agents used for the treatment of diseases and conditions in the areas of urology and oncology
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical products, preparations and agents used for the treatment of diseases and conditions in the areas of urology and oncology
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical products, preparations and agents used for the treatment of diseases and conditions in the areas of urology and oncology
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and substances for the treatment of endocrinological conditions and disorders; pharmaceutical products and substances for treatment in the field of fertility; pharmaceutical products and substances for the prevention and treatment of urological diseases, disorders and conditions, diabetes insipidus, constipation, chronic bowel disease, arthritis, autoimmune diseases and disorders, cancer, reproductive health diseases, disorders and conditions, pain, hormonal diseases, disorders and conditions
23.
POLYMERIC FILMS AND METHODS OF PREPARATION THEREOF
The present disclosure relates to polymeric films comprising a high viscosity hydroxypropylmethyl cellulose and a low viscosity hydroxypropylmethyl cellulose, methods of preparing such polymeric films and uses thereof. The polymeric films may be loaded with pharmaceutically active agents and may find particular application in the controlled delivery of such pharmaceutically active agents. In particular, the polymeric films may be suitable for vaginal administration.
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
25.
COMPOSITIONS AND METHODS FOR TREATMENT OF INFERTILITY IN MALES
Methods, uses and compositions including rFSH including α2,3- and α2,6-sialylation for use in the treatment of infertility in a male patient are described.
Methods using and compositions including FSH for use in the treatment of infertility are described, wherein the dose is selected based on the patient's age to optimise cumulative efficiency and/or reduce OHSS risk.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
27.
COMPOSITION COMPRISING LACTOBACILLUS SPECIES FOR VAGINAL THERAPIES
Microbiota restoration therapy compositions and methods for making and using microbiota restoration therapy compositions are disclosed. One example method is a method for enhancing the immune system of a patient. The method may include administering a microbiota restoration therapy composition to a patient with a primary condition. The method may also include administering a treatment for the primary condition to the patient. The treatment may be designed to treat the primary condition.
A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 35/02 - Antineoplastic agents specific for leukemia
C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
C07D 215/50 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
C07D 215/52 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
33.
SMALL MOLECULE PROSTAGLANDIN F RECEPTOR ANTAGONISTS
C07D 215/52 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
Methods, uses and products including a recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation and menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age≥35 are described.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
35.
COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION
Products and pharmaceutical compositions comprising recombinant follicle stimulating hormone (FSH) and recombinant human chorionic gonadotropin (hCG) for use in the treatment of infertility (e.g. by controlled ovarian stimulation).
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
36.
METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
The disclosure relates to compositions comprising progesterone microparticles, methods of making such compositions, and therapeutic uses thereof. In particular, the disclosure relates to progesterone-containing compositions in which hyaluronic acid, or a salt form thereof, is used as the diluent.
Described herein are aqueous pharmaceutical compositions comprising peptide Met-Glu-His-Phe-Pro-Gly-Pro (SEQ ID NO: 1), or a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt of any thereof, and therapeutic methods using them.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of orthopaedic diseases and conditions; Biopharmaceutical preparations for the treatment of orthopaedic diseases and conditions
The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may be used to improve or prepare solutions for use in protein purification and/or protein extraction processes. One particular application of the disclosed method is in affinity chromatography where it may be applied to the preparation of load solutions.
C07D 215/227 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
C07D 215/52 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
45.
SMALL MOLECULE PROSTAGLANDIN F RECEPTOR ANTAGONISTS
C07D 215/227 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
C07D 215/52 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Described are extended release drug-loaded microparticles, pharmaceutical compositions comprising them, methods of making them, and therapeutic methods using them.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical products, preparations and agents used for the treatment of diseases and conditions in the areas of reproductive health, fertility, gynaecology and obstetrics
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present disclosure provides methods of detection and diagnosis of ectopic endometriosis. The disclosure further provides compositions, medicaments and methods for treating or preventing ectopic endometriosis.
Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
Escherichia coli strain thereby treating the subject.
The subject invention also provides new bacteriophage strains.
The present disclosure relates to methods for preparing peptide salts, in particular pharmaceutically acceptable peptide salts, such as salts of atosiban (e.g. atosiban pamoate). The present disclosure further extends to the preparation of particles of such salts, such as via a spray drying process.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical preparations and agents for the treatment of orthopedic diseases, disorders and conditions; pharmaceutical and biopharmaceutical preparations and agents used for the treatment of diseases and conditions in the area of orthopaedics for the treatment of lumbar disc herniation
55.
Methods of treating prostate cancer with GnRH antagonist
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Disclosed herein are small molecule follicle-stimulating hormone (FSH) receptor modulators, methods of making them, and therapeutic methods using them.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; dietetic food and substances
adapted for medical use; dietary supplements for humans;
medical preparations. Surgical and medical apparatus and instruments. Education; arranging, organizing and conducting of
educational and scientific events and forums; publication of
printed matter, including in electronic form (other than for
advertising purposes). Medical services; human healthcare services; medical
information services.
Disclosed is a method for preparing compounds with improved stereoselectivities. The described compounds are useful intermediates and may find particular application in the synthesis of compounds containing an octahydrobenzoquinoline moiety (e.g. an octahydrobenzo[g]quinoline moiety), such as quinagolide and its derivatives. Also disclosed is a method for stereoselectively (e.g. enantioselectively) preparing an intermediate used in the existing manufacturing process for the synthesis of quinagolide this intermediate also finding utility in the synthesis of other compounds containing an octahydrobenzo[g]quinoline moiety, in particular those having a substituent at the 3- position on the octahydrobenzo[g]quinoline.
C07C 229/34 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
C07C 227/32 - Preparation of optical isomers by stereospecific synthesis
A solid pharmaceutical formulation comprising a mixture of (1) lyophilized granules comprising sildenafil or a pharmaceutically acceptable salt thereof as active ingredient and (2) a non-lyophilized composition, wherein the formulation comprises 35% to 50% by weight of the lyophilized granules (1) and dissolves in the oral cavity and the non-lyophilized composition (2) is a solid blend composition comprising flow enhancing agents, a package containing the formulation, and a process for the manufacture of the formulation.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and biopharmaceutical products, preparations, and agents used for the treatment of diseases and conditions in the areas of endocrinology, urology, oncology, reproductive health, fertility, gynaecology, obstetrics, gastroenterology, orthopaedics; pharmaceutical and biopharmaceutical agents used for the treatment of diseases and disorders emanating from microbiota dysfunction; dietary supplements for humans Medical services; human healthcare services
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Described herein are aqueous pharmaceutical compositions comprising lidocaine, hyaluronic acid, and chondroitin sulphate (or a pharmaceutically acceptable salts of any thereof) and water, as well as methods of making such aqueous pharmaceutical compositions, and therapeutic methods using them.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Described herein are processes for preparing enzalutamide nanocrystals, compositions and pharmaceutical compositions comprising them, and therapeutic methods using them.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Synthetic peptide pharmaceutical preparations for inducing and augmenting bone formation and repair; synthetic growth-factor peptides applied to orthopedic medical devices and materials for use with invasive and non-invasive medical procedures, namely, synthetic growth-factor peptide pharmaceutical preparations for inducing and augmenting bone formation and repair
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations in the therapeutic area of fertility and reproductive health; medical preparations in the therapeutic area of fertility and reproductive health
(2) Surgical instruments, medical apparatus and instruments for reconstitution and administration of pharmaceutical preparations, namely, syringes for injections, injection devices for pharmaceutical products, namely, syringes and injection pens, implantable subcutaneous drug delivery devices, injectors for medical purposes, pessaries, aerosol dispensers for medical purposes, enema kits (1) Education in the field of fertility and reproductive health; arranging, organizing and conducting of educational and scientific events and forums in the field of fertility and reproductive health; publication of printed matter, including in electronic form (other than for advertising purposes)
(2) Medical services in the field of fertility and reproductive health; human healthcare services in the field of endocrinology, reproductive health, fertility, gynecology and obstetrics; medical information services, namely providing information in the field of human health care related to endocrinology, reproductive health, fertility, gynecology and obstetrics; medical services, consultancy, information and advisory services in the field of pharmaceutical products related to endocrinology, reproductive health, fertility, gynecology, and obstetrics and treatments; medical and health care information services related to endocrinology, reproductive health, fertility, gynecology and obstetrics
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07K 7/02 - Linear peptides containing at least one abnormal peptide link
This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
75.
Recombinant FSH composition for controlled ovarian stimulation
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
C07K 16/26 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and preparations for the treatment of diseases and conditions in the areas of reproductive health, fertility, gynecology and obstetrics; drug delivery agents in the form of vaginal suppositories that facilitate the delivery of pharmaceutical preparations to the body
The invention provides a pharmaceutical composition comprising activated carbon particles, for oral administration. The pharmaceutical composition may be for (use in) the treatment of gastrointestinal fistula.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical research and development services for others in the fields of synthetic bioactive peptides and custom compositions and coatings for medical device implants for use in surgical procedures
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and preparations for the prevention and treatment of urological diseases, disorders and conditions; pharmaceutical products and preparations for the prevention and treatment of diabetes insipidus; pharmaceutical products and preparations for the prevention and treatment of autoimmune diseases and disorders; pharmaceutical products and preparations for the prevention and treatment of hormonal diseases, disorders and conditions; pharmaceutical products and preparations for the prevention and treatment of endocrinological diseases, disorders and conditions
The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
81.
COMPOSITIONS AND METHODS FOR INTRAUTERINE INSEMINATION (IUI)
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
82.
COMPOSITIONS AND METHODS FOR INTRAUTERINE INSEMINATION (IUI)
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Methods, uses and compositions including rFSH including a2,3-and a2,6-sialylationfor use in the treatment of infertility in a male patient are described.
Methods, uses and compositions including rFSH including α2,3- and α2,6-sialylation for use in the treatment of infertility in a male patient are described.
The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
87.
Method of manufacturing a pharmaceutical composition
A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Methods, uses and products including a recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation and menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age ≥35 are described.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
92.
HP-HMG FOR USE IN THE TREATMENT OF INFERTILITY IN A PATIENT WITH POLYCYSTIC OVARY SYNDROME
Described are assisted reproductive technology compositions and methods using highly purified menotropin (HP-hMG) to stimulate follicle development, particularly in women who have been diagnosed with oligoovulation and/or PCOS and who are predicted to have a high ovarian response to controlled ovarian stimulation.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
The invention provides a polypeptide dimer comprising two gp130-Fc fusion peptides for use in the treatment of ASCVD in human patients, preferably of high-risk ASCVD in human patients, more preferably of very-high-risk ASCVD in human patients.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and preparations; gene-based
pharmaceutical products and preparations; pharmaceutical
products and preparations against cancer; pharmaceutical
products and preparations against bladder diseases; sanitary
preparations for medical purposes.
95.
COMPOSITION COMPRISING HP-HMG FOR USE IN TREATING INFERTILITY
The present invention relates to improved assisted reproductive technology for women predicted to have a high ovarian response to controlled ovarian stimulation that comprise targeting a threshold serum hCG level by the final day of stimulation.
A61B 17/435 - Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo transplantation
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Compositions and methods for treating patients are disclosed. An example composition may include a vaginal microbiota composition. The vaginal microbiota composition may include a mixture of bacteria. The mixture of bacteria may include Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii, and Lactobacillus rhamnosus.
The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may be used to improve or prepare solutions for use in protein purification and/or protein extraction processes. One particular application of the disclosed method is in affinity chromatography where it may be applied to the preparation of load solutions.
The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may be used to improve or prepare solutions for use in protein purification and/or protein extraction processes. One particular application of the disclosed method is in affinity chromatography where it may be applied to the preparation of load solutions.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical products and preparations for the treatment of cancer, bladder diseases and disorders, urinary and urinary tract diseases and disorders; pharmaceutical products and preparations for use in urology; gene-based pharmaceutical products and preparations for the treatment of cancer, bladder diseases and disorders, urinary and urinary tract diseases and disorders; gene-based pharmaceutical products and preparations for use in urology; pharmaceutical products and preparations for the treatment of cancer; pharmaceutical products and preparations for the treatment of bladder diseases.
Described herein are pharmaceutical compositions comprising diclofenac and therapeutic methods for using them effective with once daily administration.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 9/00 - Medicinal preparations characterised by special physical form
